ヘルスとヘルスケア
中国和印度可以帮助阻止“疫苗民族主义”吗？
我们进入了新冠肺炎大流行的第二年，世界上绝大多数地区都迫切需要获得能够让生活恢复至正常水平的疫苗。疫苗的快速开发可能是整个大流行中最激发信心的事情——疫苗的平均开发时间已经从5-10年缩短到不到1年。尽管开发时间短，但这些疫苗的功效很强，堪称科学奇迹。然而，国家内部的疫苗分发以及国家之间的疫苗分发，就远谈不上奇迹了。
Nina Rawal
Dr. Nina Rawal is Partner and Co-Head of Trill Impact Ventures, Europe's leading impact investing house. She previously headed the life science investment team at Industrifonden, a USD 800m VC fund. Previous experience also includes Boston Consulting Group in Stockholm and New York, and VP Strategy and Ventures at Gambro (Baxter Group). She serves on the boards of Cinclus Pharma and Stockholms Sjukhem, a non-profit hospital organization.
Nina holds a MSc in Biomedicine and a PhD in Molecular Neurobiology, both from the Karolinska Institute with research work done at Columbia University and Hopital la Salpetriere. Recognition for her work includes the selection as a WEF Young Global Leader and a '40 under 40 - European Young Leader.
最新記事
ヘルスとヘルスケア
Could India and China help stop ‘vaccine nationalism’?
As we move into a second year of the COVID-19 pandemic, an overwhelming part of the world desperately awaits access to vaccines that hold the power to return life to a version of normal. ...
ヘルスとヘルスケア
Why lockdowns aren't the best way forward for the Global South
As we move further into the COVID-19 pandemic it is becoming increasingly clear that many of the tools and measures deployed by high-income countries against the virus are most probably n...